.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Helen Ajufo, MD

Articles

Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

June 14th 2023

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.